Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
Evorpacept, cetuximab, and pembrolizumab demonstrated antitumor activity in a preclinical HIS-PDX model and clinical trial in refractory MSS colorectal cancer; however, immune-related adverse events prompted early termination of study enrollment. Evidence of innate and adaptive antitumor immune activation was identified. The role of SIRPα/CD47 blockade in the treatment of MSS colorectal cancer needs to be further elucidated in future trials.
Authors
- Emily Baiyee (ORCID: https://orcid.org/0009-0000-7262-6078)
- S. Lindsey Davis (ORCID: https://orcid.org/0000-0003-3899-9481)
- Christopher H. Lieu (ORCID: https://orcid.org/0000-0002-4852-4642)
- Sunnie S. Kim (ORCID: https://orcid.org/0009-0008-3871-5112)
- Patrick J. Blatchford (ORCID: https://orcid.org/0000-0003-1714-7263)
- Howard S. Höchster (ORCID: https://orcid.org/0000-0002-9893-1529)
- Junxiao Hu (ORCID: https://orcid.org/0000-0002-5937-7916)
- Aaron J. Scott (ORCID: https://orcid.org/0000-0002-0301-3072)
- Adrian T.A. Dominguez (ORCID: https://orcid.org/0000-0003-3387-7805)
- Kimberly Rae Jordan (ORCID: https://orcid.org/0000-0001-8380-7157)
- Julie Lang (ORCID: https://orcid.org/0000-0003-2424-8222)
- Nicole Balmaceda (ORCID: https://orcid.org/0000-0001-5223-5440)
- Adrie van Bokhoven (ORCID: https://orcid.org/0000-0002-6059-2429)
- Alexis D. Leal (ORCID: https://orcid.org/0000-0002-0652-8151)
- Stacey M. Bagby (ORCID: https://orcid.org/0009-0005-3355-3861)
- Robert W. Lentz (ORCID: https://orcid.org/0000-0002-7207-8195)
- Patrick M. Boland (ORCID: https://orcid.org/0000-0002-4213-8847)
- Raymond Wadlow (ORCID: https://orcid.org/0000-0003-1959-5406)
- Todd M. Pitts (ORCID: https://orcid.org/0000-0002-8123-9894)
- Wells A. Messersmith (ORCID: https://orcid.org/0000-0003-2349-0885)
- Kristen Spencer (ORCID: https://orcid.org/0000-0001-5577-3439)
- Hannah R. Robinson (ORCID: https://orcid.org/0000-0002-9150-8015)
- Cameron A. Binns (ORCID: https://orcid.org/0009-0005-0529-5930)
Institutions
- Rutgers, The State University of New Jersey (US)
- University of Arizona (US)
- Colorado School of Public Health (US)
- Inova Fairfax Hospital (US)
- Johnson University (US)
- NYU Langone Health (US)
- Virginia Cancer Institute (US)
- University of Colorado Cancer Center (US)
- Arizona Oncology (US)
- University of Arizona Cancer Center
- Rutgers Cancer Institute (US)
- University of Colorado Anschutz Medical Campus (US)
- New York University (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-10-31
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0332
- Citations
- 2
- Primary Topic
- Phagocytosis and Immune Regulation
- Type
- article
- Field-Weighted Citation Impact
- 1.59